5 Colorectal Cancer 1 1 0 13 13 375 http://clinicaltrials.dfhcc.harvard.edu/trials/375 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with monoclonal antibody therapy and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective after surgery in treating colon cancer. (As of 6/1/2005, patients will no longer receive irinotecan on this study.) PURPOSE: This randomized phase III trial is comparing three different combination chemotherapy regimens to see how well they work when given with or without cetuximab in treating patients who have undergone surgery for stage III colon cancer. (As of 6/1/2005, patients will no longer receive irinotecan on this study.) Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 3 1249 http://clinicaltrials.dfhcc.harvard.edu/trials/1249 Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the lung, colon, or pancreas and also have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots in patients after abdominal or orthopedic surgery and in patients who suffer from a severe medical illness. Based on these studies, we are investigating to see if it prevents thrombosis in people with certain types of cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 3 319 http://clinicaltrials.dfhcc.harvard.edu/trials/319 Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy. The purpose of this research study is to determine if Cetuximab improves the benefits of neoadjuvant chemoradiotherapy when given with 5-FU and radiation therapy. The epidermal growth factor (EGF) receptor, which is found in rectal cancer, is a specific part of the cancer that is felt to encourage tumor growth. Cetuximab targets and blocks the EGF receptor and has been shown to be safe and effective in treating colorectal cancer and head and neck cancers. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 2 458 http://clinicaltrials.dfhcc.harvard.edu/trials/458 Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and cetuximab together with radiation therapy works in treating patients with HIV and stage I, stage II, or stage III anal cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 2 100 http://clinicaltrials.dfhcc.harvard.edu/trials/100 Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer The purpose of this research study is to learn whether panitumumab helps treat colorectal cancer in participants who have not responded to treatment with cetuximab. Panitumumab is a human monoclonal antibody. Antibodies are proteins that recognize a foreign substance in the body and then attach themselves to it making it exposed to destruction. Panitumumab attaches itself to a protein on cancer cells called "epidermal growth factor receptor" or EGFR. EGFR helps cancer cells to grow, and blocking EGFR helps prevent cancer cells from growing. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 2 1326 http://clinicaltrials.dfhcc.harvard.edu/trials/1326 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with intensity-modulated radiation therapy works in treating patients undergoing surgery for locally advanced rectal cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 2 67 http://clinicaltrials.dfhcc.harvard.edu/trials/67 Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II portion) patients with locally advanced rectal cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 1/Phase 2 262 http://clinicaltrials.dfhcc.harvard.edu/trials/262 Pertuzumab, Cetuximab, and Irinotecan in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer RATIONALE: Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pertuzumab together with cetuximab and irinotecan may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of pertuzumab when given together with cetuximab and irinotecan and to see how well they work in treating patients with previously treated locally advanced or metastatic colorectal cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 1/Phase 2 261 http://clinicaltrials.dfhcc.harvard.edu/trials/261 Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer In this study, the investigational drug, temsirolimus, will be combined with cetuximab, a biologic agent used in the treatment of colorectal cancer. Cetuximab in combination with temsirolimus may be more effective in treating advanced colorectal cancer than cetuximab alone. The purpose of this research study is to try to define the highest dose of cetuximab that can be used safely in combination with temsirolimus to treat advanced colorectal cancer that has progressed through standard therapy. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 1 339 http://clinicaltrials.dfhcc.harvard.edu/trials/339 ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer This research study will test the safety of the investigational drug, ZD6474, in combination with 2 other drugs that are standard in the treatment of colon and rectal cancer (cetuximab and irinotecan). ZD6474 blocks the action of two substances in the body: vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). VEGFR stimulates the formation of new blood vessels. When cancer cells produce VEGFR, new blood vessels are made that provide blood to the cancer cells. The blood carries nutrients and oxygen, allowing the cancer cells to live and grow. EGFR controls how quickly cells grow and multiply. Both of these substances are found on normal cells, but they are found in much higher levels on cancer cells. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer Phase 1 49 http://clinicaltrials.dfhcc.harvard.edu/trials/49 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas Colonoscopy is the current state-of-the-art screening procedure for detecting colorectal cancers. However, compliance with this screening procedure by the public is very low for a variety of reasons. New screening tools are needed to improve detection of colon cancer. Biomarkers from stool, urine, serum, tissue and plasma may provide valuable initial screening tools to sort the population into those that need colonoscopy and those that most likely do not. This is a cross-sectional study of subjects undergoing clinically-indicated colonoscopy or who have diagnosed colorectal cancer who are willing to provide biospecimens. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer N/A 96 http://clinicaltrials.dfhcc.harvard.edu/trials/96 Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue. Recruiting 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer N/A 1340 http://clinicaltrials.dfhcc.harvard.edu/trials/1340 Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Colorectal, Breast or Lung Cancer Older individuals account for one-third of new cancer cases and cancer-related deaths in the United States. Older individuals are more susceptible to having a decrease in physical and mental function following chemotherapy treatment. Geriatric assessment may provide a way to identify those older individuals at greatest risk of functional decline before treatment starts and during the period of treatment. Geriatric assessment includes a set of screening questions and tests designed to determine the physical and mental status of the individual at a point in time. Geriatric assessment also includes review of medications and other medical conditions the individual may have that may affect function. The investigators are conducting this study to determine if older individuals are able to complete the geriatric assessment using a computer format and how that corresponds to their treating physician's assessment of their functional status before and after starting a new chemotherapy treatment for colon, rectal, breast or lung cancer. The investigators will also evaluate the usefulness of a computerized form of geriatric assessment. Recruiting 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer N/A